Engineering a BMP2-risedronate complex with sustained release for osteoporosis therapy.

ABSTRACT: Human bone morphogenetic protein 2 (BMP2) is a key inducer of osteogenesis; however, conventional delivery systems often result in burst release and adverse effects. To address this limitation, we fabricated an ionic complex of BMP2 with the clinically used osteogenesis inducer risedronate drug through an ion-pairing method. Fourier-transform infrared spectroscopy and ultra-resolution imaging confirmed the electrostatic interactions between BMP2 and risedronate. The resulting BMP2-risedronate complex exhibited a uniform particle size of 326 ± 149 nm, a polydispersity index of 0.2-0.3, and a zeta potential of - 38.08 ± 0.12 mV. The complex demonstrated a high complexation efficiency (˃ 95%). In vitro bioactivity studies using C2C12 myoblast cells demonstrated that BMP2, combined with risedr

SUBMITTER: Jeon SO 

PROVIDER: S-EPMC12589347 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature